MENU

MBIO Stock Mustang Bio (MBIO, $0.21) price exceeded its 50-day Moving Average on January 06, 2025

A.I.dvisor
at Tickeron.com
Loading...
MBIO - Mustang Bio
Moving Avg. signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Moving Avg. signal
Price: $0.214
Daily change: -$0.0042 (-1.92%)
Daily volume: 12.8M
Capitalization: $10.6M
Industry: Biotechnology
This price move could indicate a change in the trend, and may be a sell signal for investors. A.I.dvisor found 40 similar cases, and were successful. Based on this data, the odds of success are

MBIO in -6.72% downward trend, falling for three consecutive days on December 19, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MBIO declined for three days, in of 358 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

MBIO broke above its upper Bollinger Band on January 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MBIO entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBIO's RSI Indicator exited the oversold zone, of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on January 02, 2025. You may want to consider a long position or call options on MBIO as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MBIO just turned positive on December 26, 2024. Looking at past instances where MBIO's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

MBIO moved above its 50-day moving average on January 07, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MBIO advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.746) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). MBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (264.084).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company which develops novel immunotherapy''s

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
377 Plantation Street
Phone
+1 781 652-4500
Employees
80
Web
https://www.mustangbio.com